粒生素在治疗化疗导致白细胞减少中的临床应用  

Clinical Application of Lishengsu for Treatment of Leukopenia Induced by Chemotherapy

作　　者：姜宁西[1] 张强[1] 张百红[1] 张红[1] 

机构地区：[1]兰州军区兰州总医院,兰州730050

出　　处：《中国实验血液学杂志》2003年第1期96-98,共3页Journal of Experimental Hematology

摘　　要：为观察粒生素 (rhG CSF)在治疗恶性肿瘤化疗所致白细胞减少的疗效及临床不良反应 ,对 32 7例次恶性肿瘤化疗所致白细胞减少的患者使用粒生素 2 .5 - 5 μg (kg·d) ,皮下注射。结果表明 :Ⅰ和Ⅱ度骨髓抑制白细胞恢复正常所用粒生素的平均剂量为 2 37μg ,Ⅲ和Ⅳ度为 6 75 μg。治疗总有效率为 99.4 %。临床应用中未发现明显副反应。结论 :粒生素在治疗恶性肿瘤化疗所致的白细胞减少中具有良好的临床有效性和安全性。The efficacy and safety of Lishengsu (a rhG CSF preparation) were evaluated for treatment of chemotherapy induced leukopenia. 327 cases of leukopenia with grade Ⅰ Ⅳ induced by chemotherapy were subcutaneously administered at 2.5-5.0 μg/(kg·d) of Lishengsu, and hemogram and the side effects were observed. The results showed that Lishengsu had satisfactory effect to cure leukopenia after chemtherapy, with an effective rate of 99.4% (325/327), the side effects were quite slight. It is concluded that Lishengsu is efficient and safe for patients with leukopenia, and can be used as an adjuvant drug for treatment of leukopenia after chemotherapy.

关 键 词：粒生素 重组人粒细胞集落刺激因子 化学治疗 白细胞减少 

分 类 号：R557.1[医药卫生—血液循环系统疾病]